title: First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation.
abstract: BACKGROUND
  Nuclear protein in testis (NUT) midline carcinomas (NMC) are characterized by rearrangements of the gene NUT. In the majority of NMCs, a translocation t(15;19), resulting in a BRD4/NUT fusion gene, is present. Nuclear protein in testis midline carcinomas is a rare, but probably underdiagnosed entity due to misdiagnosis. Most cases have been reported in the mediastinum and upper aero-digestive tract. The clinical course of a NMC is extremely aggressive, in spite of intensive chemotherapy and radiotherapy, with an average survival < 1 year.
  
  
  RESULTS
  A 32-year-old man presented with a pre-auricular swelling on the left side. After partial parotidectomy, the diagnosis of a NMC was made based on the presence of t(15;19)(q14;p13.1) and BRD4/NUT fusion gene demonstrated by fluorescence in situ hybridization (FISH). During postoperative radiotherapy, the patient developed bone metastases for which chemotherapy consisting of cisplatine, doxorubicine and ifosfamide (PAI) was initiated with remarkable clinical and radiological improvement. Nevertheless, the response was not durable.
  
  
  CONCLUSIONS
  This case illustrates that responses to chemotherapy in the palliative treatment of a t(15;19)-translocated salivary gland carcinoma are possible but not durable.
authors.affiliation: a Department of Oncology , Integrated Cancer Center , Ghent , Belgium.|b Department of General Medical Oncology , UZ Leuven , Belgium.
authors.forename: Christof
authors.initials: C
authors.lastname: Vulsteke
authors.affiliation: c Department of Imaging and Pathology , KU Leuven , Belgium.
authors.forename: Eveline
authors.initials: E
authors.lastname: Lurquin
authors.affiliation: d Department of Human Genetics , KU Leuven , Belgium.
authors.forename: Maria
authors.initials: M
authors.lastname: Debiec-Rychter
authors.affiliation: c Department of Imaging and Pathology , KU Leuven , Belgium.
authors.forename: Olivier
authors.initials: O
authors.lastname: Gheysens
authors.affiliation: e Department of Radiation Oncology , UZ Leuven , Belgium.|f Department of Oncology , KU Leuven , Belgium.
authors.forename: Sandra
authors.initials: S
authors.lastname: Nuyts
authors.affiliation: g Department of Oral Health Sciences , KU Leuven , Belgium.
authors.forename: Joseph
authors.initials: J
authors.lastname: Schoenaers
authors.affiliation: g Department of Oral Health Sciences , KU Leuven , Belgium.
authors.forename: Constantinus
authors.initials: C
authors.lastname: Politis
authors.affiliation: h Department of Medical Oncology , Jessa Ziekenhuis , Hasselt , Belgium.
authors.forename: Jeroen
authors.initials: J
authors.lastname: Mebis
authors.affiliation: c Department of Imaging and Pathology , KU Leuven , Belgium.
authors.forename: Esther
authors.initials: E
authors.lastname: Hauben
authors.affiliation: b Department of General Medical Oncology , UZ Leuven , Belgium.|f Department of Oncology , KU Leuven , Belgium.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Clement
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002277:Carcinoma / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D009687:Nuclear Proteins / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D010307:Parotid Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D011878:Radiotherapy; D016896:Treatment Outcome
chemical_list: C471990:BRD4-NUT fusion oncogene protein, human; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion; D004317:Doxorubicin; D002945:Cisplatin; D007069:Ifosfamide
keywords: BRD4/NUT fusion gene; Chemotherapy; Nut midline carcinoma